A Phase 2b Randomized, Single-Center, Double Blind, Placebo Controlled, 2-Arm Study to Investigate Orally Administered Combination Therapies (5-alpha Reductase Inhibitor + Raloxifene) Compared With Monotherapy (5-alpha Reductase Inhibitor + Placebo) in Adult Patients With Benign Prostatic Hyperplasia (BPH)

SRD5A2 is a critical enzyme for prostatic development and growth, and the SRD5A2 inhibitor, finasteride, is used to treat benign prostatic hyperplasia (BPH). SRD5A2 is absent in 30% of normal adult men, which explains the resistance of a subset of patients to this commonly prescribed drug. This project proposes new combination therapies (5-ARI+raloxifene) and evaluates novel non-invasive biomarkers, based on alternative pathways that lead to prostatic enlargement.

Start Date03 Dec 2025

Sponsor / Collaborator

Beth Israel Deaconess Medical Center, Inc.

[+1]

NCT06062810

/ Active, not recruitingPhase 2/3

Explore the Relationship Between Single Nucleotide Polymorphisms and Raloxifene Response and Toxicity in Patients With Breast Cancer LCIS

Explore the relationship between drug target ER gene single nucleotide polymorphisms and Raloxifene therapeutic effects in patients with Breast Cancer LCIS, based on Oxford precisely sequencing drug targets' genes.
Explore the relationship between drug target UGT gene single nucleotide polymorphisms and Raloxifene side-effects in patients with Breast Cancer LCIS, based on Oxford precisely sequencing drug targets' genes.

Start Date21 Jun 2025

Sponsor / Collaborator

Medicine Invention Design, Inc.

NCT06055179

/ RecruitingNot ApplicableIIT

Mechanistic and Pharmacokinetic Studies of Classical Chinese Formula Xiao Chai Hu Tang (XCHT) Against Irinotecan-Induced Gut Toxicities(Clinical Study Part:Randomized Controlled Trial)

Randomized double-blind placebo-controlled trial (RCT) study, to determine the impact of XCHT on irinotecan-induced severe delayed-onset diarrhea (SDOD), and to determine the feasibility of using plasma raloxifene-4'-glucuronide as a probe for intestinal UGT activity.

Start Date08 Mar 2024

Sponsor / Collaborator

Guangzhou University of Chinese Medicine

[+1]

100 Clinical Results associated with Raloxifene Hydrochloride

100 Translational Medicine associated with Raloxifene Hydrochloride

100 Patents (Medical) associated with Raloxifene Hydrochloride

4,300

Literatures (Medical) associated with Raloxifene Hydrochloride

31 Dec 2026·GYNECOLOGICAL ENDOCRINOLOGY

Effects of estradiol, tamoxifen, and raloxifene on human temporal lobe cortex astroglial cell spreading

Article

Author: Williamson, Anne ; Silva, Ivaldo ; J. Li, Howard ; Spencer, Dennis ; Fadiel, Ahmed ; Oliveira Santana, Vinicius ; Naftolin, Frederick Nicholas

BACKGROUND:

Astrocytes, once regarded as passive support cells, are recognized as active regulators of synaptic organization and neuronal integration. Through extension or retraction of their processes, astrocytes influence synapse formation and elimination. Astrocytes express estrogen receptors, and animal studies have shown that estradiol modifies astrocytic morphology in relation to synaptic density.

OBJECTIVE:

To examine the effects of estradiol and two clinically available selective estrogen receptor modulators (SERMs), tamoxifen, and raloxifene on astrocyte processes in human brain tissue.

METHODS:

Human temporal lobe cortical slices were incubated for 60 min with estradiol (10 nM), tamoxifen (1.0 µM), or raloxifene (1.0 µM), and the results were compared with untreated control slices. Astrocytes were visualized by immunostaining for the glial cytoskeletal marker glial fibrillary acidic protein (GFAP). Light microscopy image analysis was used to quantify astrocytic process thickness and branching, using Neurolucida® software.

RESULTS:

Control slices exhibited astrocytic branch extension and thinning during the incubation period. Similar morphological changes were observed in the tamoxifen-treated slices. In contrast, raloxifene treatment was associated with a significant reduction in astrocyte branching and thinning compared with controls (p = 0.01 for primary processes). Estradiol treatment resulted in intermediate reductions in astroglial process measures that did not reach statistical significance.

CONCLUSIONS:

Estradiol, tamoxifen, and raloxifene - widely used hormonal agents - were associated with distinct effects on astrocyte morphology in human cortical tissue. These findings support a role for estrogen receptor modulation in astroglial structural regulation and suggest a potential cellular mechanism contributing to central nervous system symptoms reported in clinical settings.

01 Feb 2026·EUROPEAN JOURNAL OF PHARMACOLOGY

Genomic and AI-driven discovery in chronic prostatitis: Causal role of ITPR3 and therapeutic repurposing of raloxifene

Article

Author: Zuo, Ling ; Huang, Zhibin ; Dong, Xuan ; Li, Yutong ; Sun, Ruixu ; Gao, Liangmeng ; Song, Xingyu ; Liu, Hongwei

BACKGROUND:

This study employed an integrative multi-omics strategy to investigate the potential role of inositol 1,4,5-trisphosphate receptor type 3 (ITPR3) in chronic prostatitis and to identify potential therapeutic targets and drugs using a mendelian randomization (MR)-proteomics causal inference framework.

OBJECTIVES:

To investigate the potential role of ITPR3 in chronic prostatitis and to identify potential therapeutic targets and drugs.

METHODS:

We harmonized multi-omics data from eQTLGen (blood eQTLs, n = 31,684), UKB-PPP (plasma pQTLs, n = 54,219), and FinnGen (GWAS for chronic prostatitis: the discovery cohort 4160 cases/130,139 controls and replication cohort 4743 cases/141,300 controls). A two-sample bidirectional MR approach was applied to assess causal relationships between druggable genes and chronic prostatitis. The SMR-HEIDI analysis was conducted to exclude linkage disequilibrium confounding, followed by co-expression network construction and functional enrichment analysis to explore biological pathways. ITPR3 inhibitors were predicted using the DSigDB platform, with binding affinity evaluated through molecular docking and ADME properties analyzed via the SwissADME.

RESULTS:

MR analysis revealed that each 1-standard deviation increase in genetically predicted ITPR3 expression was associated with a 32.8 % higher risk of chronic prostatitis (OR = 1.328, 95 % CI: 1.108-1.702, P < 0.001), which was further validated by SMR-HEIDI testing (HEIDI P > 0.05). Functional enrichment analysis suggested that ITPR3 may contribute to chronic prostatitis progression through TGF-β/SMAD7 inflammatory pathway and calcium signaling dysregulation, while co-expression network analysis indicated its association with Th17 cell differentiation. Molecular docking demonstrated high binding affinity between raloxifene and ITPR3, and ADME profiling indicated favorable oral bioavailability without significant CYP450 inhibition risk, complying with Lipinski's rule.

CONCLUSION:

ITPR3 is a novel therapeutic target for chronic prostatitis, and the computational repurposing of raloxifene as its inhibitor warrants further experimental investigation. These findings provide new insights for developing clinical interventions in chronic prostatitis.

01 Feb 2026·MedComm

HSD17B7 Counters Bone Loss in Estrogen Deficiency via Estrogen Receptor Stabilization and Mediates the Effect of Raloxifene

Article

Author: Zhang, Junyue ; Yoon, Sun‐Jung ; Kim, Jung Ryul ; Chen, Si ; Jang, Kyu Yun ; Song, Yiping ; Moon, Young Jae ; Koo, Jeong‐Hyun

ABSTRACT:

Estrogen receptor (ER) α is a central regulator of osteoclasts in osteoporosis induced by estrogen deficiency. ERα is regulated through interactions with various coactivators; however, the precise mechanisms of these interactions are not yet fully understood. We screened for proteins that bind to ERα using LC–MS/MS and identified a physical interaction between HSD17B7 and ERα, specifically ERα binding to the 119–172 domain of HSD17B7. This interaction blocked ubiquitin–proteasomal degradation of ERα and increased ERE activity. Estrogen‐deficient mice lacking HSD17B7 in their preosteoclasts showed more severe bone loss than control mice. This was attributed to increased mitochondrial biogenesis through the activation of PLD1–mTOR signaling. Additionally, in preosteoclasts derived from patients with severe osteoporosis, the expression of HSD17B7 and ERα was significantly reduced compared to the control subjects. Finally, raloxifene, which boosts ERα, did not inhibit bone loss without HSD17B7, confirming the modulation of ERα through HSD17B7. Therefore, HSD17B7 regulation is a novel therapeutic approach for alleviating estrogen‐deficient osteoporosis.

News (Medical) associated with Raloxifene Hydrochloride

10 Sep 2024

·www.drugs.com

Review Weighs Treatments for Genitourinary Symptoms of Menopause

TUESDAY, Sept. 10, 2024 -- Vaginal estrogen, vaginal dehydroepiandrosterone (DHEA), oral ospemifene, and vaginal moisturizers may be beneficial for some genitourinary symptoms of menopause (GSM), according to a review published online Sept. 10 in the Annals of Internal Medicine . Elisheva R. Danan, M.D., M.P.H., from the University of Minnesota in Minneapolis, and colleagues examined the effectiveness and harms of vaginal estrogen, nonestrogen hormone therapies, and vaginal moisturizers for treatment of GSM in a systematic review of randomized controlled trials (RCTs). A total of 46 RCTs assessing vaginal estrogen, nonestrogen hormones, vaginal moisturizers, or multiple interventions were identified from 11,993 citations. The researchers found that vaginal estrogen may improve vulvovaginal dryness, dyspareunia , the most bothersome symptom, and treatment satisfaction compared with placebo or no treatment. Vaginal DHEA may improve dryness, dyspareunia, and distress, bother, or interference from genitourinary symptoms compared with placebo; oral ospemifene may improve dryness, dyspareunia, and treatment satisfaction; and dryness may also be improved by vaginal moisturizers (all low certainty of evidence [COE]). No benefit or uncertain effects (low and very low COE, respectively) may be provided by vaginal testosterone, systemic DHEA, vaginal oxytocin, and oral raloxifene or bazedoxifene. Reporting was limited by studies of short duration that were insufficiently powered to assess infrequent serious harms. "Future studies would be strengthened by standard definitions of symptoms and uniform diagnostic criteria for GSM, a common set of validated outcome measures and reporting standards, and attention to clinically relevant patient populations and intervention comparisons," the authors write.

Clinical Result

24 May 2023

·www.biospace.com

New Data Reveal Role of SARS-Cov-2 Spike Protein in Covid-19 Associated Coagulopathy

Unprecedented comprehension of the interaction between Spike and the Human Estrogen Receptor Alfa provides insights for a new generation of anti SARS-CoV-2 and pan-Coronavirus vaccines Italian and US researchers have revealed how the SARS-CoV-2 Spike protein interacts with human Estrogen Receptor-α (ERα) leading to severe coagulopathy observed in COVID-19 patients. The new data - published in Nature’s Signal Transduction and Targeted Therapy - shows that point mutations in the sequence of SARS-CoV-2 Spike (S)-protein eliminate its pro-coagulation effect without compromising immunogenicity. The findings provide actionable insights for designing vaccines lacking of estrogen-receptor mediated side effects for all coronavirus strains and other viral infections. MILAN & SAN MATEO, Calif.--(BUSINESS WIRE)-- Dompé farmaceutici announced today new peer-reviewed data demonstrating that small changes in the SARS-CoV-2 Spike (S)-protein sequence can eliminate its effect in inducing coagulation1. The tendency for the Spike protein to stimulate inflammatory and coagulation has been implicated in coagulopathy observed in the lungs, heart and kidneys of COVID-19 patients with a similar and extremely rare effects observed in a minority of patients who received COVID-19 vaccines. This press release features multimedia. View the full release here: Framework Dompé farmaceutici Biotech production (Photo: Business Wire) Data stemmed from the EXSCALATE supercomputing calculation predicted a potential function of Spike (S) as a co-factor for human ERα nuclear signalling. This interaction is mediated by a nuclear receptor co-regulator (NRC) LXD-like motif present on the viral protein S2 subunit, and the activation function 2 (AF-2) region on ERα2. This work builds on other recent studies3,4 showing that coagulopathy is clearly associated with the interaction of the SARS-CoV-2 Spike (S) protein with the human Erα. While circulating estrogens play a protective role by regulating the immune response to infection, modulation of ERα signalling in SARS-CoV-2-infected lung tissue stimulates proinflammatory signals leading to hypertrophy, vasoconstriction, and vessel obstruction. In the new article the scientists of the italo-american collaboration (encompassing Centro Cardiologico Monzino in Italy and the National Institute on Drug Abuse and the Johns Hopkins School of Medicine in the US) demonstrated that the interaction between the Spike protein and ERα leads to an increase in tissue factor (TF) and the overall pro-coagulation activity in two human endothelial cell lines. The results were further validated by overexpressing S-protein in mice. This pro-coagulative function of Spike in vitro and in vivo, was abolished or strongly reduced by the variants of the Spike proteins carrying mutations in the interaction domain with ERα (as predicted by EXSCALATE). “The value and benefits of vaccines in countering the COVID-19 pandemic remain unquestionable and overwhelming compared to the risks associated with infection from SARS-CoV-2” underscores Maurizio Pesce, a research Group Leader at the Monzino Cardiology Center in Milan, Italy, and initiator of the study in 2021 together with the leading Silvia Barbieri, another research Group Leader at Monzino, “We hope that our findings will be considered in the development of the next generation of vaccines reducing the residual side effects and risks. Our data also unravel a new function of the viral protein in direct regulation of thrombosis associated factors. This has general implications not only for COVID-19, but for other viral infections altering the coagulation pro patients”. “This continuing research is critical to understand the pathogenetic mechanisms associated with SARS-CoV2 infection and causal mechanisms of some rare COVID-19 vaccine side effects,” says Dompé farmaceutici Chief Scientific Officer Marcello Allegretti “Ongoing expanding data is revealing a well-conserved region with the same characteristics of the LXD-like motif present on the viral protein S2 subunit, also in other Coronaviruses. This evidence could open new scenarios in ‘pan-Coronavirus’ vaccination. We are excited to identify a path toward further refinement strategies to enable even more powerful benefits through future vaccination and booster initiatives”. ____________________________________________________________________________________ About Dompé Dompé is a private, rapidly scaling international biopharmaceutical company founded in Milan, Italy, with a 130-year legacy of medical innovation. The R&D department of the company is anchored by EXSCALATE, a structure-based virtual screening platform developed in-house that leverages one of the most powerful supercomputing and artificial intelligence platforms in the world. Today, Dompé employs more than 800 employees worldwide and maintains a US commercial operations hub in the San Francisco Bay Area as well as an R&D presence in Boston. Forward Looking Statements This press release refers to certain information that may not coincide with expected future results. Dompé firmly believes in the soundness and reasonableness of the concepts expressed. However, some of the information is subject to a certain degree of indetermination in relation to its research and development activities and the necessary verifications to be performed by regulatory bodies. Therefore, as of today, Dompé cannot guarantee that the expected results will be consistent with the information provided above. 1. SS Barbieri et al. Relevance of the viral Spike protein/cellular Estrogen Receptor-α interaction for endothelial-based coagulopathy induced by SARS-CoV-2 - Signal Transduction and Targeted Therapy - 2. Allegretti, M. et al. Repurposing the estrogen receptor modulator raloxifene to treat SARS-CoV-2 370 infection. Cell Death Differ. 29, 156-166 (2022). 371 - 3. Wilcox et al. Sex Differences in Thrombosis and Mortality in Patients Hospitalized for COVID-19, Am J Cardiol. 2022 May 1; 170: 112–117 - 4. Science Advances - The SARS-CoV-2 spike protein binds and modulates estrogen receptors - eadd4150 (2022) 30 November 2022 -

Vaccine

24 May 2023

·www.dompe.com

New Data Reveal Role of SARS-Cov-2 Spike protein in Covid-19 associated coagulopathy

Italian and US researchers have revealed how the SARS-CoV-2 Spike protein interacts with human Estrogen Receptor-α (ERα) leading to severe coagulopathy observed in COVID-19 patients. Italian and US researchers have revealed how the SARS-CoV-2 Spike protein interacts with human Estrogen Receptor-α (ERα) leading to severe coagulopathy observed in COVID-19 patients. The new data - published in Nature’s Signal Transduction and Targeted Therapy - shows that point mutations in the sequence of SARS-CoV-2 Spike (S)-protein eliminate its pro-coagulation effect without compromising immunogenicity. The findings provide actionable insights for designing vaccines lacking of estrogen-receptor mediated side effects for all coronavirus strains and other viral infections. The new data - published in Nature’s Signal Transduction and Targeted Therapy - shows that point mutations in the sequence of SARS-CoV-2 Spike (S)-protein eliminate its pro-coagulation effect without compromising immunogenicity. The findings provide actionable insights for designing vaccines lacking of estrogen-receptor mediated side effects for all coronavirus strains and other viral infections. MILAN, Italy and SAN MATEO, Calif. | 22 May, 2023 - Dompé farmaceutici announced today new peer-reviewed data demonstrating that small changes in the SARS-CoV-2 Spike (S)-protein sequence can eliminate its effect in inducing coagulation [1]. The tendency for the Spike protein to stimulate inflammatory and coagulation has been implicated in coagulopathy observed in the lungs, heart and kidneys of COVID-19 patients with a similar and extremely rare effects observed in a minority of patients who received COVID-19 vaccines. Data stemmed from the EXSCALATE supercomputing calculation predicted a potential function of Spike (S) as a co-factor for human ERα nuclear signalling. This interaction is mediated by a nuclear receptor co-regulator (NRC) LXD-like motif present on the viral protein S2 subunit, and the activation function 2 (AF-2) region on ERα [2]. This work builds on other recent studies [3], [4] showing that coagulopathy is clearly associated with the interaction of the SARS-CoV-2 Spike (S) protein with the human Erα. While circulating estrogens play a protective role by regulating the immune response to infection, modulation of ERα signalling in SARS-CoV-2-infected lung tissue stimulates proinflammatory signals leading to hypertrophy, vasoconstriction, and vessel obstruction. In the new article the scientists of the italo-american collaboration (encompassing Centro Cardiologico Monzino in Italy and the National Institute on Drug Abuse and the Johns Hopkins School of Medicine in the US) demonstrated that the interaction between the Spike protein and ERα leads to an increase in tissue factor (TF) and the overall pro-coagulation activity in two human endothelial cell lines. The results were further validated by overexpressing S-protein in mice. This pro-coagulative function of Spike in vitro and in vivo, was abolished or strongly reduced by the variants of the Spike proteins carrying mutations in the interaction domain with ERα (as predicted by EXSCALATE). “The value and benefits of vaccines in countering the COVID-19 pandemic remain unquestionable and overwhelming compared to the risks associated with infection from SARS-CoV-2” underscores Maurizio Pesce, a research Group Leader at the Monzino Cardiology Center in Milan, Italy, and initiator of the study in 2021 together with the leading Silvia Barbieri, another research Group Leader at Monzino, “We hope that our findings will be considered in the development of the next generation of vaccines reducing the residual side effects and risks. Our data also unravel a new function of the viral protein in direct regulation of thrombosis associated factors. This has general implications not only for COVID-19, but for other viral infections altering the coagulation profile of patients”. “This continuing research is critical to understand the pathogenetic mechanisms associated with SARS-CoV2 infection and causal mechanisms of some rare COVID-19 vaccine side effects,” says Dompé farmaceutici Chief Scientific Officer Marcello Allegretti “Ongoing expanding data is revealing a well-conserved region with the same characteristics of the LXD-like motif present on the viral protein S2 subunit, also in other Coronaviruses. This evidence could open new scenarios in ‘pan-Coronavirus’ vaccination. We are excited to identify a path toward further refinement strategies to enable even more powerful benefits through future vaccination and booster initiatives”. [1] SS Barbieri et al. Relevance of the viral Spike protein/cellular Estrogen Receptor-α interaction for endothelial-based coagulopathy induced by SARS-CoV-2 - Signal Transduction and Targeted Therapy [2] Allegretti, M. et al. Repurposing the estrogen receptor modulator raloxifene to treat SARS-CoV-2 370 infection. Cell Death Differ. 29, 156-166 (2022). 371 [3] Wilcox et al. Sex Differences in Thrombosis and Mortality in Patients Hospitalized for COVID-19, Am J Cardiol. 2022 May 1; 170: 112–117 [4] Science Advances - The SARS-CoV-2 spike protein binds and modulates estrogen receptors - eadd4150 (2022) 30 November 2022

Vaccine

100 Deals associated with Raloxifene Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D02217	Raloxifene Hydrochloride	G03XC01	DB00481

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Breast Cancer	United States	Eli Lilly & Co.	13 Sep 2007
Osteoporosis, Postmenopausal	United States	Eli Lilly & Co.	09 Dec 1997

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Phase 3	Italy	-	23 Oct 2020
Cardiovascular Diseases	Phase 3	United States	Eli Lilly & Co.	01 Jun 1998
Coronary Disease	Phase 3	United States	Eli Lilly & Co.	01 Jun 1998
Invasive Mammary Carcinoma	Phase 3	United States	Eli Lilly & Co.	01 Jun 1998
Hemorrhagic Fever, Ebola	Phase 2	Italy	Dompe Farmaceutici SpA	30 Jan 2022
Hepatitis B	Phase 2	Italy	Dompe Farmaceutici SpA	30 Jan 2022
Hepatitis C, Chronic	Phase 2	Italy	Dompe Farmaceutici SpA	30 Jan 2022
Zika Virus Infection	Phase 2	Italy	Dompe Farmaceutici SpA	30 Jan 2022
Hot Flashes	Phase 2	United States	Eli Lilly & Co.	01 Feb 2002
Hyperhidrosis	Phase 2	United States	Eli Lilly & Co.	01 Feb 2002

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05172050 (CTgov)	Phase 2/3	COVID-19	61	Raloxifene (Raloxifene 60 mg)	ixocvawnfc = pgjsnyjvzt gpkdvwfznx (ifknrwdsoi, dhpeufamnr - banzxkqege) View more	-	14 Dec 2023
				Raloxifene (Raloxifene 120 mg)	ixocvawnfc = erkvpbfipu gpkdvwfznx (ifknrwdsoi, zctrniiokn - dzwujijpwh) View more
ERA2020	Not Applicable	Chronic Kidney Diseases	39,128	Osteoporosis medications (bisphosphonates, raloxifene, teriparatide, or denosumab)	yfnctupvjd(jfbhofuazn) = ltpzrnxigh azsyhqbaai (fohtpkmmbw ) View more	Negative	06 Jun 2020
2020 ARVO Annual Meeting (ARVO2020)	Phase 2	Brain Injuries, Traumatic	-	Raloxifene 5 mg/kg	aslrpcpqzk(tweyunixzj) = reduced or eliminated ymdofewhgm (lnutkkyggf ) View more	Positive	01 Jun 2020
				Raloxifene 10 mg/kg
NCT00687102 (Co-STAR, CTgov)	Phase 3	Cognition	1,498	tamoxifen (Star Participants Assigned to Tamoxifen)	zzkxpngonf(ygnhifbltv) = hgajgmgoxj tvbxtitqsp (sndicmfvws, 0.34) View more	-	23 Jan 2018
				raloxifene (Star Participants Assigned to Raloxifene)	zzkxpngonf(ygnhifbltv) = sxammafbiq tvbxtitqsp (sndicmfvws, 0.32) View more
NCT01280305 (Pubmed \| J Clin Psychiatry)	Phase 3	Schizoaffective disorder \| Schizophrenia	200	Raloxifene 120 mg/d plus antipsychotics	hegtydfquu(jrvupnjqhr): P-Value = < .001	Negative	01 Jul 2017
				Placebo plus antipsychotics
NCT00427700 (CTgov)	Phase 3	Polycystic Ovary Syndrome	82	Clomiphene citrate (Clomiphene)	lusvebvhsn = qfmgssrzan alxepjpbmu (asbtdtrewc, lnxjiyqhyp - rplwybhcqd) View more	-	06 Oct 2016
				raloxifene (Raloxifene)	lusvebvhsn = tlpvltmqsw alxepjpbmu (asbtdtrewc, kdgmkggofz - dxctvuxlhc) View more
NCT00030147 (CTgov)	Phase 4	Depressive Disorder	65	Placebo skin patch and placebo tablets (Placebo)	uytvisjjgy(kkvscxotuy) = rydrtltbrp qaayaqbxgt (zcfqfeoink, 9) View more	-	05 Sep 2016
				Raloxifene (Raloxifene)	uytvisjjgy(kkvscxotuy) = swebowkbeu qaayaqbxgt (zcfqfeoink, 7.9) View more
NCT00361543 (Pubmed \| JAMA Psychiatry)	Phase 4	Schizophrenia, Treatment-Resistant	56	Raloxifene hydrochloride	gcbgzotdcl(neqrmzokgb): β = -1.92 View more	Positive	01 Sep 2016
				Placebo
NCT00368459 (CTgov)	Phase 2	Alzheimer Disease	42	raloxifene (Raloxifene)	lamhbqxsju(xiqitovcsu) = bqlwhmfdnt gbwzfogarh (wgqwcknxzw, 5.8) View more	-	02 Apr 2015
				Placebo (Placebo)	lamhbqxsju(xiqitovcsu) = eauniyzjdv gbwzfogarh (wgqwcknxzw, 8.0) View more
NCT01166958 (CTgov)	Phase 4	Osteoporosis	26	Teriparatide (Daily Teriparatide (Forteo))	fpevocsitn(obdjyvlmso) = mxiujazgig kgrqjsxhtg (krxsbaewky, loitqiakaw - yjdhymnjwo) View more	-	22 Sep 2014
				Raloxifene+Teriparatide (Monthly Cycles of Teriparatide Followed by Raloxifene)	fpevocsitn(obdjyvlmso) = cttrxjechl kgrqjsxhtg (krxsbaewky, rpyymizezj - spfjonxzdh) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis